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Background: Compound Kushen Injection (CKI) is a Chinese patent medicine
approved by the China Food and Drug Administration for the treatment of various types
of solid tumors. CKI, combined with transarterial chemoembolization (TACE), is believed
to increase the therapeutic efficacy of unresectable hepatocellular carcinoma (HCC).
We report an updated and extended meta-analysis with detailed outcomes of both the
efficacy and adverse events (AEs) of CKI combined with TACE therapy.
Materials and methods: Electronic databases, including PubMed, Embase, the
Cochrane Library, the Chinese Biomedical Database (CBM), Wanfang, the VIP medicine
information system (VMIS) and the China National Knowledge Infrastructure (CNKI), were
examined for relevant articles before November 13, 2015. An odds ratio (OR) was used
to estimate tumor response (TR), Karnofsky Performance Scale (KPS) improvement,
Child-Pugh (CP) improvement, survival rate (SR) and AEs. A publication bias and a
subgroup analysis were also assessed.
Results: Eighteen studies, with a total of 1,338 HCC patients who met the criteria
for the meta-analysis, were included. TR, KPS improvement and CP improvement
were significantly enhanced for the combination therapy compared to TACE alone
(OR = 1.84, 95% CI: [1.46, 2.33], P < 0.00001; OR = 2.37, 95% CI: [1.76,
3.18], P < 0.00001; OR = 1.81, 95% CI: [1.08, 3.03], P = 0.02, respectively).
The combination therapy was associated with an improvement in 1-year and 2-year
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SRs but not an improved 3-year SR (OR = 2.40; 95% CI: [1.59, 3.62], P < 0.0001;
OR = 2.49, 95% CI: [1.24, 5.00], P = 0.01; OR = 2.49, 95% CI: [0.94, 6.61], P = 0.07,
respectively). A safety analysis indicated that AEs (including nausea/vomiting, fever,
hepatalgia, increased transaminase, increased bilirubin and leukopenia) were reduced
for the combination treatment compared to TACE alone.
Conclusion: The combination treatment of TACE and CKI was associated with
improved TR, KPS and CP improvement and improved 1- and 2-year SRs in patients
with unresectable HCC. The 3-year SR was not improved. The combination therapy
resulted in a reduction in AEs. The findings of this study should be interpreted with
caution because of the small sample size and study limitations.
Keywords: Compound Kushen Injection, transarterial chemoembolization, unresectable hepatocellular
carcinoma, meta-analysis, systematic review
INTRODUCTION
Hepatocellular carcinoma is a health problem worldwide. More
than 700,000 cases of HCC are diagnosed every year (Forner
et al., 2012). HCC is the third cause of cancer-related deaths and
the 16th absolute cause of death globally (Lozano et al., 2012).
There has been a 62% increase in the number of HCC-related
annual deaths over the last 20 years (from 463,000 to 752,000).
The majority of HCC cases (80%) occur in sub-Saharan Africa
and eastern Asia. The incidence rate is greater than 20 per 100,000
individuals (El-Serag, 2012; Llovet and Hernandez-Gea, 2014).
The situation is particularly concerning in China. China accounts
for 55% of HCC cases worldwide (Qin et al., 2013).
Surgery and liver transplant options are limited for HCC
because only 30% of cases are diagnosed at an early stage that
is amenable for resection, transplantation or local ablation with
radiofrequency (European Association for the Study of The Liver
and European Organisation For Research and Treatment Of
Cancer, 2012). The remaining 70% are at an advanced stage with
few therapeutic options. Transarterial chemoembolization is the
current standard treatment for intermediate stage HCC. TACE
significantly increases the SR in patients with unresectable HCC
compared to supportive care or suboptimal therapies according
several randomized trials and meta-analyses (Cammá et al., 2002;
Llovet et al., 2002; Lo et al., 2002; Llovet and Bruix, 2003).
However, approximately 50% of patients do not benefit from
TACE (Lammer et al., 2010). A retrospective study demonstrated
that 64% of patients received a second cTACE, but only a
few patients (26%) received a third cTACE (Terzi et al., 2012).
Several AEs (post embolization syndrome, hepatic insufficiency
and myelosuppression) are associated with TACE therapy. The
identification of new drugs that could be combined with TACE
may enhance its therapeutic efficacy and reduce AEs.
Abbreviations: 5-FU, fluorouracil; ADM, adriamycin; AEs, adverse events;
CBM, Chinese Biomedical Database; CF, calcium folinate; CKI, Compound
Kushen Injection; CI, confidence interval; CNKI, China National Knowledge
Infrastructure; CP, Child-Pugh; DDP, cisplatin; EPI, epirubicin; GS, gelatin sponge;
HCC, hepatocellular carcinoma; HCPT, hydroxycamptothecin; KPS, Karnofsky
Performance Scale; M-H, Mantel-Haenszel; MMC, mitomycin; NR, not report;
OR, odds ratio; RCTs, randomized clinical trials; SR, survival rate; SE, standard
error; TACE, transarterial chemoembolization; THP, pirarubicin; TR, tumor
response; VMIS, VIP medicine information system.
Compound Kushen Injection is a Chinese patent medicine
extracted from two medical herbs, Radix Sophorae Flavescentis
and Rhizoma Smilacis Glabrae. It is approved by the China Food
and Drug Administration (CFDA) for the treatment of various
types of solid tumors. The main compounds in CKI are matrine,
oxymatrine and sophoridine. These compounds are associated
with liver protection and the treatment of viral hepatitis and HCC
in China (Zhou et al., 2012; Wang et al., 2015; Parvez et al.,
2016). The combination of CKI and TACE may increase the
therapeutic efficacy of unresectable HCC treatment. A previous
meta-analysis also confirmed that CKI plus TACE was superior
to TACE alone in the treatment of unresectable HCC (TR, quality
of life and 1-year SR) (Sun et al., 2011). We report an updated
and extended meta-analysis with detailed outcomes for efficacy
and AEs (Figure 1).
MATERIALS AND METHODS
Literature Search Strategy
This meta-analysis was performed according to the PRISMA
statement (Moher et al., 2009). Seven databases, including
PubMed, Embase, the Cochrane Library, the CBM, Wanfang,
the VMIS and the CNKI, were examined for original articles
published before November 13, 2015. All searches were
performed without language limitations to identify all relevant
trials. The following initial search items were used: “HCC”
[Title/Abstract] OR “hepatic tumor” [Title/Abstract] OR “liver
cancer” [Title/Abstract] AND “CKI” [Title/Abstract] OR “Yan
Shu Injection” [Title/Abstract]. The searched results were
downloaded into Endnote software (version X7, Thomson
Reuters, Inc., New York, NY, USA) for further screening.
Review Strategy and Selection Criteria
The literature searches were performed using Endnote software.
Duplicate records were deleted. Two investigators (Xiao Ma
and Yin-Qiu Huang) independently performed the title/abstract
review and the full-text review. Disagreements between the two
investigators were resolved by consensus and discussion.
Studies that met the following inclusion criteria were
considered eligible for this meta-analysis: (1) trials were
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FIGURE 1 | Work flow of present study.
described as RCTs; (2) study subjects or patients were confirmed
cytologically or pathologically, or diagnosed by computed
tomography (CT) with HCC; (3) patients in the experimental
group received TACE-based therapy with CKI, whereas patients
in the control group received TACE-based therapy only; and (4)
a minimum of two of the following outcomes were included in
each study: TR, KPS improvement, CP improvement, SR or AEs.
Trials were excluded if they did not meet the following criteria:
(1) reviews, comments, case report, editorials, letters, or articles
unrelated with the topics; (2) trials were not RCTs; (3) diagnostic
criteria were not clearly reported in trials; and (4) the intervention
of HCC patients was not based on TACE treatment.
Data Extraction and Methodological
Quality Assessment
Two independent investigators (Xiao Ma and Cong-En Zhang)
extracted the following information from the selected studies:
first author, year of publication, sample size regimens and
outcome measures. If the identical trial appeared in different
publications, reports with the most relevant information were
discussed and included by investigators.
The methodological quality was evaluated according to the
Cochrane Handbook for Systematic Reviews of Interventions
(Deeks et al., 2011). The evaluation was performed as follows:
selection bias, performance bias, detection bias, attrition bias,
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reporting bias and other biases. The quality judgment of each
term was assessed using three levels: ‘Low risk’ of bias (adequate
and correct description of methods or procedures), ‘High risk’ of
bias (incorrect description of methods or procedures) or ‘Unclear
risk’ of bias (no description of methods and procedures).
Statistical Analysis
The analysis was conducted using Review Manager 5.3 (Cochrane
Collaboration, Oxford, UK). Outcome measures, such as TR, KPS
improvement, CP improvement, SR and AEs (Supplementary
Table S1), were considered dichotomous variables. These
parameters were expressed as an OR with 95% CI for each study.
Heterogeneity among studies was estimated using the Cochran’s
Q statistic and I2 tests. A P-value <0.1 or an I2 > 50% were
defined to have heterogeneity (Higgins et al., 2003). A fixed-
effects model was used to pool the estimates when heterogeneity
was absent. A random-effects model was used to pool the
estimates when there was obvious heterogeneity. Funnel plots
were used to detect publication bias.
RESULTS
Identification of Eligible Studies
A total of 560 potential articles were identified from the databases,
and 336 articles were excluded after duplicate review. A total of
224 articles were excluded for title screening, and 171 articles
were excluded because of irrelevant themes or experiments. Fifty
three articles remained for full-text review.
In the review, 35 studies were excluded for the following
reasons: 6 studies were single-arm designs, 7 studies were
not clearly confirmed and diagnosed with HCC, 11 studies
involved ambiguous therapies in the intervention group, 8
studies did not present definite outcome measures and 3
studies presented overlapping data with another study. Eighteen
studies (Huang et al., 2006; Yang, 2006; Chen et al., 2007;
Cao et al., 2009; Deng et al., 2009; Wang and Chen, 2009;
Yu et al., 2009; Tong, 2010; Xu et al., 2010; Yu and Kang,
2010; Qu et al., 2011; Wang et al., 2011; Zhang and Tian,
2011; Zuo et al., 2011; Han et al., 2012; Li et al., 2013; Sun,
2014; Tian, 2014) that had a total of 1,338 HCC patients
who met the criteria for the meta-analysis were included
(Figure 2).
Study Characteristics and Quality
Assessment
The baseline characteristics of the included studies are presented
in Supplementary Table S2. Among the 18 studies (Huang et al.,
2006; Yang, 2006; Chen et al., 2007; Cao et al., 2009; Deng
et al., 2009; Wang and Chen, 2009; Yu et al., 2009; Tong,
2010; Xu et al., 2010; Yu and Kang, 2010; Qu et al., 2011;
Wang et al., 2011; Zhang and Tian, 2011; Zuo et al., 2011; Han
et al., 2012; Li et al., 2013; Sun, 2014; Tian, 2014) conducted
between 2006 and 2014, all were RCTs with a comparison
between a combination of CKI and TACE and TACE treatment
alone. The age of the patients ranged from 25 to 79 years.
FIGURE 2 | Study selection process for the meta-analysis.
Seventeen studies reported the stages of HCC and 13 mentioned
KPS. The TACE treatment regimen varied greatly. However, the
combination of 5-FU, DDP, MMC, EPI or DDP in the TACE
treatment was the most common regimen. One study did NR
the embolizing agents of TACE. Lipiodol was the embolizing
agent in the remaining studies. The dose of administered CKI
ranged from 15 to 30 mL/day. In the majority of studies, CKI
was administered for 15 days via intravenous drip (Table 1). All
trials mentioned “randomization,” but only four trials stated the
appropriate generation of the random allocation sequence (Yang,
2006; Wang and Chen, 2009; Yu and Kang, 2010; Zuo et al.,
2011). No trials described information on allocation concealment
and blinding. Seven trials (Yang, 2006; Chen et al., 2007; Wang
and Chen, 2009; Xu et al., 2010; Qu et al., 2011; Zuo et al.,
2011; Li et al., 2013) mentioned over exclusion of participants
or drop-outs. Selective reporting was low for the 14 trials (Yang,
2006; Chen et al., 2007; Cao et al., 2009; Wang and Chen, 2009;
Yu et al., 2009; Tong, 2010; Xu et al., 2010; Yu and Kang,
2010; Qu et al., 2011; Zuo et al., 2011; Han et al., 2012; Li
et al., 2013; Sun, 2014; Tian, 2014) (Figure 3, Supplementary
Figure S1).
Tumor Response
Seventeen studies (Huang et al., 2006; Yang, 2006; Chen et al.,
2007; Cao et al., 2009; Deng et al., 2009; Wang and Chen, 2009;
Yu et al., 2009; Tong, 2010; Xu et al., 2010; Yu and Kang,
2010; Wang et al., 2011; Zhang and Tian, 2011; Zuo et al.,
2011; Han et al., 2012; Li et al., 2013; Sun, 2014; Tian, 2014)
provided the TRs (Figure 4). A meta-analysis of these studies
using a fixed-effect model demonstrated that CKI combined with
TACE therapy significantly improved the TR in the treatment of
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TABLE 1 | Intervention characteristics of the included trials.
Study (years) TACE treatment drugs Embolizing
Agents
CKI dosage and method Duration Outcome measures
Tian, 2014 5-FU + DDP + MMC Lipiodol 20 mL/day, intravenous drip 6 weeks TR, AEs
Zuo et al., 2011 5-FU + DDP + MMC Lipiodol 20 mL/day, intravenous drip 14 days TR, AEs
Sun, 2014 5-FU + DDP + MMC Lipiodol 20 mL/day, intravenous drip 15 days/course, 3
courses
TR, KPS, AEs
Li et al., 2013 5-FU + DDP + MMC Lipiodol 20 mL/day, intravenous drip 2 weeks/course, 2
courses
TR, KPS, CP, AEs
Han et al., 2012 EPI Lipiodol 15 mL/day, intravenous drip 45 days TR, KPS, CP, AEs
Zhang and Tian,
2011
5-FU + EPI + MMC Lipiodol 20 mL/day, intravenous drip 20 days/course, 3
courses
TR, AEs
Wang et al., 2011 5-FU+EPI+MMC Lipiodol 20 mL/day, intravenous drip 15 days/course, 2
courses
TR, KPS, AEs
Qu et al., 2011 CF+5-Fu+DDP Lipiodol 20 mL/day, intravenous drip 14 days/course, 2
courses
KPS, SR, AEs
Tong, 2010 5-FU + DDP + EPI Lipiodol 20 mL/day, intravenous drip 14 days/course, 2
courses
TR, AEs
Xu et al., 2010 CF + 5-Fu + DDP + THP or HCPT Lipiodol 20 mL/day, intravenous drip 15 days/course, 2
courses
TR, KPS, SR, AEs
Yu and Kang, 2010 5-FU + ADM + HCPT Lipiodol 20 mL/day, intravenous drip 15 days/course, 3
courses
TR, KPS, AEs
Cao et al., 2009 5-FU + DDP + MMC Lipiodol 20 mL/day, intravenous drip 2 weeks TR, KPS, AEs
Yu et al., 2009 5-FU + HCPT NR 20 mL/day, intravenous drip 14 days/course, 2
courses
TR, SR, AEs





5-FU + ADM + DDP Lipiodol 20 mL/day, intravenous drip 10 days TR, KPS, SR
Chen et al., 2007 5-FU + EPI + MMC Lipiodol 20 mL/day, intravenous drip 2–3 weeks/course, 3
courses
TR, KPS, SR, AEs
Yang, 2006 5-FU + MMC + ADM Lipiodol + GS 20 mL/day, intravenous drip 20 days TR, KPS, SR
Huang et al., 2006 5-Fu + ADM + HCPT Lipiodol + GS 15–30 mL/day, intravenous drip 10–20 days/course,
2–4 courses
TR, KPS, AEs
CKI, Compound Kushen Injection; TACE, Transarterial chemoembolization; 5-FU, fluorouracil; DDP, cisplatin; MMC, mitomycin; EPI, epirubicin; CF, calcium folinate; THP,
pirarubicin; HCPT, hydroxycamptothecin; ADM, adriamycin; NR, not report; GS, gelatin sponge; TR, tumor response; AEs, adverse events; KPS, Karnofsky Performance
Scale; CP, Child-Pugh; SR, survival rate.
unresectable HCCs (OR= 1.84, 95% CI: 1.46, 2.33; P < 0.00001).
No statistically significant heterogeneity (P = 0.97, I2 = 0%) was
found among individual trials.
KPS Improvement
There were 10 trials (Huang et al., 2006; Yang, 2006; Chen
et al., 2007; Cao et al., 2009; Wang and Chen, 2009; Xu
FIGURE 3 | Risk of bias assessment in the included trials. The quality assessment was performed by Review Manager 5.3 according to the Cochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0. The red square indicates a high risk of bias. The green square indicates a low risk of bias, and the
blank square indicates an unclear risk of bias.
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FIGURE 4 | Forest plot of the TR in patients treated with CKI + TACE therapy and TACE alone. I2 and P are the criterion for the heterogeneity test,  pooled
OR, –– OR and 95% CI.
FIGURE 5 | Forest plot of KPS improvement and CP improvement in patients treated with CKI + TACE therapy and TACE alone. (A) Forest plot of KPS
improvement; (B) Forest plot of CP improvement. I2 and P are the criterion for the heterogeneity test,  pooled OR, –– OR and 95% CI.
et al., 2010; Yu and Kang, 2010; Wang et al., 2011; Han
et al., 2012; Li et al., 2013) that demonstrated a KPS
improvement of >10 points. The pooled OR revealed
that CKI combined with TACE therapy significantly
enhanced KPS improvement compared to TACE alone
(OR = 2.37, 95% CI: 1.76, 3.18; P < 0.00001). No significant
heterogeneity (P = 0.84, I2 = 0%) was found among these trials
(Figure 5A).
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FIGURE 6 | Forest plot of the SR in patients treated with CKI + TACE therapy and TACE alone. (A) Forest plot of the 1-year SR; (B) Forest plot of the 2-year
SR; (C) Forest plot of the 3-year SR. I2 and P are the criterion for the heterogeneity test,  pooled OR, –– OR and 95% CI.
Child-Pugh Improvement
Two trials (Han et al., 2012; Li et al., 2013) demonstrated CP
improvement. The pooled analysis (using a fixed-effects model)
suggested that CKI combined with TACE therapy significantly
improved CP improvement compared to TACE alone in the
treatment of unresectable HCC (OR = 1.81, 95% CI: 1.08, 3.03;
P = 0.02). No statistically significant heterogeneity (P = 0.77,
I2 = 0%) was found among individual trials (Figure 5B).
Survival Rate
Six trials (Huang et al., 2006; Yang, 2006; Chen et al., 2007;
Wang and Chen, 2009; Yu et al., 2009; Xu et al., 2010; Qu
et al., 2011) with 433 patients were identified using the 1-year SR
outcome. CKI combined with TACE therapy improved the 1-year
SR in patients with unresectable HCC compared to TACE alone
(OR = 2.40; 95% CI: 1.59, 3.62; P < 0.0001) (Figure 6A). No
heterogeneity (P= 0.96, I2 = 0%) was noted among these studies.
Three trials (Chen et al., 2007; Wang and Chen, 2009; Qu et al.,
2011) reported the 2-year SR. A fixed-effect model demonstrated
that CKI combined with TACE therapy significantly improved
the 2-year SR (OR = 2.49, 95% CI: 1.24, 5.00; P = 0.01). No
statistically significant heterogeneity (P = 0.53, I2 = 0%) was
observed among individual trials (Figure 6B). There was no
difference between CKI combined with TACE therapy and TACE
treatment alone in 3-year SR (based on two studies) (Wang and
Chen, 2009; Qu et al., 2011) (OR = 2.49, 95% CI: 0.94, 6.61;
P = 0.07). No heterogeneity (P = 0.88, I2 = 0%) was noted. The
fixed-effect model was used in the analysis (Figure 6C).
Adverse Events
Table 2 summarizes the forest plots for the AEs that occurred
during the treatment. The non-hematological AEs included
nausea/vomiting, fever, hepatalgia, increased transaminase and
increased bilirubin (Supplementary Figures S2A–F). Leukopenia
that was related to hematological AEs was recorded in eight trials
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TABLE 2 | Comparison of AEs for patients treated with CKI+TACE therapy and TACE alone.
Adverse events Trials CKI + TACE TACE Heterogeneity OR (95% CI) P-value
P I2
Nausea/Vomiting 11 94/374 173/366 1.00 0% 0.37 (0.27, 0.59) <0.00001
Fever 8 140/287 217/283 0.67 0% 0.29 (0.20, 0.42) <0.00001
Hepatalgia 6 102/216 159/212 0.42 0% 0.27 (0.17, 0.42) <0.00001
Increased transaminase 8 131/295 204/283 0.52 0% 0.27 (0.18, 0.39) <0.00001
Increased bilirubin 6 108/222 166/220 0.46 0% 0.28 (0.18, 0.43) <0.00001
Leukopenia 8 126/356 207/351 0.09 43% 0.36 (0.26, 0.49) <0.00001
I2 and P are the criterion for the heterogeneity test. The P-value indicates the significance between two arms.
FIGURE 7 | Funnel plot for the publication bias. (A) Funnel plot of the TR; (B) Funnel plot of KPS improvement.
(Huang et al., 2006; Chen et al., 2007; Cao et al., 2009; Yu and
Kang, 2010; Zhang and Tian, 2011; Han et al., 2012; Li et al., 2013;
Sun, 2014). No statistically significant heterogeneity was noted
for the non-hematological AEs (P: 0.42–1.00; I2 = 0%). A single
application of TACE alone resulted in a higher incidence of
non-hematological AEs compared to CKI combined with TACE
(P < 0.00001). CKI combined with TACE also demonstrated a
lower rate of leukopenia (P < 0.00001). The heterogeneity is
moderate (P = 0.09 and I2 = 43%).
Publication Bias
A funnel plot was used to express the publication bias. There
were 17 trials (Huang et al., 2006; Yang, 2006; Chen et al., 2007;
Cao et al., 2009; Deng et al., 2009; Wang and Chen, 2009; Yu
et al., 2009; Tong, 2010; Xu et al., 2010; Yu and Kang, 2010;
Wang et al., 2011; Zhang and Tian, 2011; Zuo et al., 2011; Han
et al., 2012; Li et al., 2013; Sun, 2014; Tian, 2014) included in the
funnel plot of the TR, and no significant asymmetry was observed
(Figure 7A). The funnel plot of KPS improvement was used to
measure publication bias. The funnel plot indicated that there was
no asymmetry in KPS improvement (Figure 7B).
DISCUSSION
Transarterial chemoembolization is one of the few effective
therapeutic treatments for unresectable HCC. However, TACE
only has a modest survival benefit (an average increase in survival
of 3 months). Additionally, TACE is a potent stimulator of neo-
angiogenesis (Cabrera et al., 2011). The observed angiogenesis
upregulates local angiogenic factors, which can promote tumor
growth. This growth increases the risk of metastases and poor
outcomes (Sergio et al., 2008). Therefore, TACE is combined
with a systemic anticancer agent, such as sorafenib. However, the
efficacy and toxicity of this combination therapy is controversial
(Park et al., 2012; Liu et al., 2014). A phase III study revealed
that TACE in combination with sorafenib did not significantly
prolong time to progression in Asian patients with HCC (Kudo
et al., 2011). A new combination therapy for unresectable HCC
patients in Asian countries is necessary.
Chinese practitioners have sought treatments for liver cancer
for a long time. Traditional Chinese medicines are increasingly
applied to enhance the efficacy of TACE and to reduce the
side effects. A recent meta-analysis indicated that traditional
Chinese medicines (used as an herbal formula) could increase
the efficacy and reduce the toxicity of TACE in patients with
unresectable HCC (Cheung et al., 2013). The Chinese patent
medicine CKI, combined with TACE, was superior compared
to TACE alone for unresectable HCC in TR, quality of life
and 1-year survival (Sun et al., 2012). We further confirmed
these results and report extended findings. CKI combined with
TACE therapy was associated with a significantly higher TR, KPS
improvement and CP improvement compared to TACE mono-
therapy (P < 0.00001, P < 0.00001, P = 0.02, respectively).
The combination therapy also improved the 1-year SR and the
2-year SR using the pooled estimates (P < 0.0001, P = 0.01,
respectively). It did not result in a statistically significant
improvement of the 3-year SR (P = 0.07). There were fewer
samples in the 3-year SR compared to the 1-year SR. This
result is based on two small-sample trials. Additional samples
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are necessary to better understand the results. The combination
therapy reduced the incidence of AEs including nausea and
vomiting, fever, hepatalgia, increased transaminase, increased
bilirubin and leukopenia (P< 0.00001). The result suggested that
CKI increases the treatment efficacy and reduces AEs in HCC
patients.
The combination therapy schedule is important in clinical
practice. Therefore, CKI treatment duration was examined. In a
subgroup analysis, the studies were divided into two durations:
(1) the duration of the consecutive treatment of CKI exceeded
3 weeks in two trials (Han et al., 2012; Tian, 2014); (2) the
duration of the remaining trials were approximately 2–3 weeks.
The schedule choice did not result in differences in TR. The
former schedule provided limited information regarding AEs
(one trial’s report). The safety of CKI treatment for greater than
3 weeks should be further examined.
CKI suppressed the growth of various liver cancer cells
such as H22 and HepG2 (Sun et al., 2011; Wang et al.,
2011). The anti-tumor mechanisms of CKI may be involved in
(1) the increased protein expression of p16, (2) the reduced
unmethylated state of the p16 gene, (3) the inhibition of VEGF
and MVD expression in neoplastic tissues, and (4) decreased
microvessel density (Wang et al., 2015). Matrine, one of the
major alkaloids in CKI, reduces cancer cell proliferation and
induces apoptosis (Ma et al., 2008; Zhang et al., 2012). CKI is
believed to be a complementary agent to TACE treatment to
inhibit the growth of liver cancer, suppress tumor metastasis
and improve the quality of life for patients with unresectable
HCC.
Extensive research and strict methodologies were employed to
select trials and analyze the efficacy and the AEs associated with
HCC treatment. However, there are limitations to this research,
such as the quality of the included data for the original trials.
Many RCTs do not employ strict methodologies. Additionally,
the majority of the studies examined Chinese patients. It is
necessary to examine the results using a more varied population
sample. The sample size, selection criteria, and TACE drugs
varied for the included studies. We were unable to perform a
subgroup analysis.
CONCLUSION
These findings indicate that TACE combined with CKI may
significantly improve TR, KPS and CP improvement and the 1-
and 2-year SR. It is likely that the combination treatment also
improves the 3-year SR, but the results were not statistically
significant. The combination therapy was also associated with
fewer AEs. However, our findings must be interpreted with
caution because of the small sample size and limitations of the
study. Several rigorous, large-scale RCTs are necessary to confirm
these results.
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